Un fabricante de envases farmacéuticos de vidrio en el que puede confiar

Seleccionar demasiado pronto un formato de envasado para productos inyectables puede generar problemas durante el aumento de escala. Un formato que respalde un lote clínico pequeño puede no ofrecer el rendimiento ni la estructura de costos necesarios para el suministro comercial, mientras que un proceso a granel diseñado para grandes volúmenes puede requerir más equipos de preparación de los que un proyecto inicial puede justificar.

Formatos a granel, RTU y PFS responden a distintas necesidades de los proyectos. Envases RTU puede reducir la preparación de los recipientes en las instalaciones del cliente, mientras que el formato a granel puede ser adecuado para operaciones consolidadas de gran volumen que cuenten con una infraestructura de procesamiento validada, y las PFS o los cartuchos pueden ser idóneos para proyectos en los que sean importantes la dosificación predeterminada y la integración con sistemas de administración de fármacos.

Before comparing the formats, it is important to separate two different decisions. Bulk and RTU describe how a container is supplied and prepared for filling, while vial, cartridge and PFS describe the primary container or drug-delivery format. A vial or cartridge may be supplied in either Bulk or RTU form, while a PFS system may also be provided in an RTU Nest & Tub configuration.

¿Cuál es la diferencia entre los envases a granel, RTU y PFS?

Los formatos a granel, RTU y PFS no son simplemente tres versiones del mismo recipiente. Representan diferentes flujos de trabajo de envasado y llenado.

Envasado a granel

En este artículo, A granel se refiere a los envases farmacéuticos convencionales de vidrio suministrados para la preparación y el llenado por parte del cliente. Según el producto y el proceso, es posible que el fabricante farmacéutico deba realizar el lavado, la despirogenización, la esterilización, el secado y la manipulación antes del llenado.

Las gamas estándar de viales y cartuchos de vidrio de LINUO incluyen opciones de envasado a granel. El proceso exacto de preparación depende del recipiente, los equipos del cliente y los procedimientos operativos.

Envases farmacéuticos RTU

Los envases listos para usar se suministran limpios, esterilizados y preparados para el llenado. LINUO ofrece viales de vidrio RTU y cartuchos de vidrio RTU for applicable aseptic filling projects.

Los viales RTU de LINUO están disponibles en Nest & Tub and Tray formats. Its RTU cartridges are available in Nest & Tub formats for cartridge-based drug-delivery systems.

Según la información publicada por LINUO, sus productos RTU aplicables se suministran sin necesidad de lavado ni despirogenización y preesterilizados. Esto puede reducir los pasos de preparación en las instalaciones del cliente, así como la necesidad de sistemas asociados de lavado con WFI y equipos de despirogenización.

PFS packaging

A prefillable syringe is designed to receive a drug before the point of administration. Combina el envase farmacéutico con una función de administración del medicamento.

LINUO provides PFS solutions in Type I borosilicate glass and COP polymer options. Published formats include staked-needle, Luer-slip and Luer-lock configurations, with applicable RTU Nest & Tub packaging.

La idoneidad de las PFS debe evaluarse según la formulación, el proceso de llenado, el sistema de componentes, los requisitos de dosificación y el dispositivo de inyección previsto.

¿Por qué influye la etapa del proyecto en la selección del envase?

La decisión sobre el envase que se toma durante las primeras fases del desarrollo puede afectar al llenado, los estudios de estabilidad, el desarrollo del dispositivo, la documentación reglamentaria y el escalado comercial.

Los proyectos clínicos iniciales pueden dar prioridad a la rapidez, la flexibilidad para trabajar con lotes pequeños y una infraestructura limitada. Los proyectos en fases avanzadas requieren mayor atención a la consistencia entre lotes, los datos de estabilidad, los procesos validados y la futura ampliación de escala. El suministro comercial añade requisitos de capacidad, costes, logística, documentación y continuidad del proveedor.

The format should therefore be evaluated against both current and future requirements.

Etapa del proyecto	Prioridades principales	Formats to Evaluate
R&D and Early Clinical	Lotes pequeños, muestras, evaluación rápida y equipos de preparación limitados	RTU vials, RTU cartridges or other project-compatible formats
Etapa clínica avanzada	Estabilidad, consistencia entre lotes, compatibilidad con la línea de llenado y documentación	Qualified Bulk or RTU formats; PFS or cartridges where the delivery format is established
Ampliación a escala comercial	Capacidad, coste total, procesos validados y continuidad del suministro	A granel o RTU según la infraestructura instalada y la estrategia de producción
Desarrollo para uso en pacientes	Dosis predeterminada, método de administración e integración con el dispositivo	Jeringas precargadas, cartuchos o sistemas relacionados con autoinyectores
Mature Commercial Supply	Repeatable processes, throughput and unit economics	Puede considerarse el formato a granel cuando ya existe un equipo de preparación validado.

Este es un marco de decisión, no una recomendación universal. El formato final debe confirmarse para el producto farmacéutico y el proceso de fabricación.

¿Cuándo puede el envasado RTU respaldar los proyectos clínicos iniciales?

Los proyectos iniciales a menudo necesitan preparar cantidades limitadas para la evaluación de la formulación, los estudios de estabilidad o el uso clínico. En esta etapa, instalar o dedicar equipos de lavado, despirogenización y esterilización puede añadir complejidad.

de LINUO Viales RTU y los cartuchos se suministran para procesos listos para el llenado. Los formatos RTU aplicables pueden reducir los requisitos del cliente asociados con:

• Container washing
• Despirogenización
• Esterilización
• Drying
• Equipos de preparación de WFI
• Depyrogenation tunnels
• Espacio de sala limpia relacionado con la preparación
• Manipulación manual de envases

Estas características pueden hacer que valga la pena evaluar el envasado farmacéutico RTU para proyectos iniciales, CDMO e instalaciones de llenado y acabado que requieren flexibilidad para lotes pequeños o que no cuentan con una infraestructura específica para la preparación de envases.

Sin embargo, el formato RTU no elimina la necesidad de:

• Cualificación de entrada
• Diseño del proceso aséptico
• Comprobaciones de compatibilidad con la línea de llenado
• Container-closure evaluation
• Drug–container compatibility studies
• Batch documentation
• Liberación final del producto farmacéutico

RTU debe seleccionarse porque se adapta al modelo operativo del proyecto, no simplemente porque el proyecto se encuentre en una etapa inicial.

¿Qué riesgos de calidad deben considerarse en el envasado clínico temprano?

Un tamaño de lote pequeño no elimina los riesgos de calidad del envasado farmacéutico. El envasado para fases clínicas iniciales aún debe ser compatible con la formulación prevista, el proceso de llenado y el programa de almacenamiento.

Important considerations include:

• Tipo de vidrio
• Resistencia hidrolítica
• Container dimensions
• Compatibilidad del cierre
• Sterile barrier format
• Método de esterilización
• Tratamiento de la superficie
• Requisitos de partículas y limpieza
• Extractables and leachables
• Batch documentation
• Storage and transport conditions

Cambiar el envase después de realizar los primeros estudios de estabilidad puede afectar la cantidad de evaluación adicional necesaria. Por lo tanto, los equipos del proyecto deben evitar seleccionar un formato temporal sin considerar si este puede respaldar el desarrollo posterior.

LINUO’s technical team can support product selection based on the drug, filling process and required performance. Samples can be supplied with applicable CoA and test data for evaluation, subject to the selected product and project.

What Changes During Late-Stage Clinical Development?

Late-stage clinical development places greater emphasis on la repetibilidad y la relación entre el envase, la formulación y la producción.

By this stage, the project may need to confirm:

• Dimensiones finales del envase
• Glass material
• Closure or plunger components
• Filling process
• Condiciones de esterilización
• Container-closure requirements
• Stability-study configuration
• Commercial filling-line compatibility
• Batch records and testing documents
• Change-control requirements
• Capacidad del proveedor y planificación de las entregas

Si se prevé utilizar contenedores a granel para la producción comercial, la transición desde RTU u otro formato para lotes pequeños debe evaluarse antes del lanzamiento comercial. Incluso cuando la geometría del contenedor parece similar, las diferencias en la preparación, la manipulación, los sistemas de barrera estéril y la presentación en la línea de llenado pueden requerir una evaluación adicional.

If the project intends to retain the RTU format, the team should confirm that the applicable Nest & Tub or Tray configuration can support the planned filling line and production volume.

Why Is Filling-Line Compatibility Important Before Scale-Up?

A packaging format must physically and operationally fit the filling process.

For glass vials, important factors can include container dimensions, nest or tray format, stopper fit, capping process and filling-line handling. For cartridges and PFS, the project must also consider inside and outside dimensions, piston or plunger movement, siliconization, closure components and device assembly.

LINUO’s RTU vials and cartridges are designed to support automated filling, stoppering, sealing and inspection processes. However, this does not mean every format can be loaded onto every filling line without verification.

Before scale-up, pharmaceutical manufacturers should confirm:

• Container and component drawings
• Filling-line interface
• Nest, tub or tray dimensions
• De-nesting or in-nest filling process
• Stoppering and capping method
• Inspection requirements
• Line-speed expectations
• Change parts or equipment adjustments
• Sample or engineering-batch trials
• Project-specific validation plan

Una declaración general de compatibilidad con líneas automatizadas no debe sustituir las pruebas realizadas en los equipos reales del cliente.

When Can Bulk Packaging Be More Suitable for Commercial Production?

Bulk packaging may be considered when a pharmaceutical manufacturer already operates validated container-preparation and high-volume filling processes.

An established commercial facility may already have:

• Sistemas de agua para inyección (WFI)
• Equipo de lavado de viales o cartuchos
• Depyrogenation tunnels
• Sterilization processes
• Automated container handling
• Bulk filling-line configuration
• Qualified cleanroom space
• Trained operating personnel
• Existing maintenance procedures

In this situation, Bulk packaging may offer commercial advantages because the customer has already invested in the required infrastructure. However, the container purchase price alone does not determine the more economical format.

A proper Bulk versus RTU packaging comparison should include:

• Container price
• Washing and sterilization costs
• WFI consumption
• Energy use
• Cleanroom space
• Equipment depreciation
• Maintenance
• Labour
• Changeover time
• Inspection
• Breakage and handling
• Validation work
• Packaging and transport
• Production volume

When Can RTU Remain Suitable for Commercial Supply?

RTU is not limited to small clinical batches. It may remain relevant during commercial production when the format matches the filling line, product risk profile and total manufacturing strategy.

LINUO’s RTU vial portfolio includes multiple vial sizes in Nest & Tub and Tray configurations. Its RTU cartridge portfolio supports applicable pen- and pump-based filling projects.

Commercial RTU evaluation should consider:

• Required annual volume
• Filling-line throughput
• Nest or Tray presentation
• Sterile barrier handling
• Supply continuity
• Batch documentation
• Sterilization-related documents
• Inspection records
• Packaging configuration
• Warehouse and logistics requirements
• Total process cost

RTU can reduce customer-side preparation steps, but this does not automatically mean it has the lowest total cost at every production volume. Commercial suitability must be assessed against Bulk processing using actual project data.

Why Do High-Value Injectable Drugs Need a Different Evaluation?

For high-value injectable products, the cost of product loss or rejected units may be more significant than the difference in empty-container price.

LINUO identifies RTU vials, cartridges and PFS solutions as possible packaging directions for biologics and other high-value injectable applications. Nest & Tub and Tray systems can reduce direct glass-to-glass contact and manual handling during applicable production and transfer processes.

When Does PFS Packaging Add Value?

PFS packaging becomes more relevant when the intended product is supplied as a prefilled dose rather than being withdrawn from a vial before administration.

LINUO’s published PFS information identifies applications including biologics, vaccines, injectable drugs and aesthetic medicine. Available options include Type I borosilicate glass and COP polymer, along with staked-needle, Luer-slip and Luer-lock formats.

Potential workflow and delivery considerations include:

• Predetermined-dose presentation
• Fewer drug-transfer steps before administration
• Component and plunger performance
• Injection-device integration
• Patient or healthcare-professional use
• Subcutaneous administration
• Self-administration
• Long-term treatment
• Auto-injector integration

The PFS system must be evaluated as a combination of barrel, plunger stopper, plunger rod, needle or Luer interface, tip cap, siliconization and sterile packaging.

PFS selection must not be based only on patient convenience. The formulation, viscosity, dose volume, contact materials, filling process, sterilization method, container-closure integrity and intended device all require project-specific confirmation.

What Supply Risks Matter During Commercial Scale-Up?

Commercial injectable packaging requires more than a technically suitable container. The supplier must also support stable capacity, materials, quality documentation and delivery planning.

LINUO operates an integrated pharmaceutical glass supply chain covering in-house glass tubing and finished packaging. Its published manufacturing information includes a 900,000+ m² manufacturing campus, 500+ core machines, annual capacity exceeding 9.6 billion units and annual glass tubing output above 13,000 tons.

These figures show manufacturing scale, but customers should still confirm product-specific capacity and delivery requirements.

A commercial supply review should include:

• Product-specific production capacity
• Forecast and order volumes
• Lead time
• Raw material security
• Backup production arrangements
• Batch consistency
• Quality and release documents
• Packaging and pallet configuration
• Warehousing
• Transport requirements
• Change control
• Complaint and investigation support
• Business-continuity planning

Commercial supply suitability should be evaluated for the selected product—not inferred only from total company capacity.

What Documentation Is Needed from Clinical to Commercial Supply?

Documentation requirements generally become more extensive as an injectable project moves toward commercial production. Depending on the selected product and project, LINUO can support product specifications, Certificates of Analysis, compliance statements, material information, batch records, inspection reports and applicable testing documents.

RTU projects may also require sterilization-related information, sterile barrier specifications, inspection records and batch-release documents. The exact document package, registration support and applicable standards should be confirmed for each product and target market.

Company-level certificates and registrations should not automatically be applied to every product configuration. Buyers should confirm the specific documentation available for the selected vial, cartridge or PFS system.

 

Can Packaging Formats Change During the Product Lifecycle?

A packaging format may be reconsidered as batch size, production equipment, administration method or commercial strategy changes.

Possible transitions include:

• RTU vial during early development to RTU vial at commercial scale;
• RTU vial during early development to Bulk vial for an established commercial line;
• Conventional vial to PFS when a prefilled dose presentation is developed;
• Standard cartridge to RTU cartridge for an applicable aseptic filling strategy;
• Vial presentation to cartridge or PFS as part of a drug-device development programme.

Any format change should trigger a review of:

• Glass or polymer material
• Container dimensions
• Closure components
• Esterilización
• Filling process
• Stability data
• Drug–container compatibility
• Container-closure integrity
• Device compatibility
• Regulatory documentation
• Supply and logistics

A later transition may require additional qualification or validation. For this reason, the anticipated commercial format should be discussed as early as practical.

How Should Buyers Compare Bulk, RTU and PFS?

No single format is the best choice for every injectable drug or project stage.

Decision factor	A granel	RTU	PFS
Customer-side container preparation	Generally required according to customer process	Reduced for applicable filling-ready formats	Reduced when supplied in applicable RTU format
Infrastructure requirement	Higher where washing and depyrogenation are performed in-house	Can reduce need for customer-side preparation equipment	Requires compatible PFS filling and component-handling process
Small-batch flexibility	Depends on existing equipment	May suit applicable clinical and flexible filling projects	Depends on filling and device-development readiness
Commercial volume	May suit established high-volume lines	Can support commercial supply where line and volume are compatible	Depends on dose presentation, filling capacity and market strategy
Drug-delivery function	Container only	Container only unless used as part of another device	Integrated packaging and delivery presentation
Patient self-administration	Not inherent	Not inherent	More relevant for applicable prefilled and device-based applications
Main qualification focus	Container preparation and filling process	Sterile barrier, filling-line integration and documentation	Formulation, components, filling, dosing and device integration
Cost evaluation	Container plus in-house processing	RTU unit cost plus reduced preparation burden	Complete syringe, component, filling and delivery-system cost

This comparison is intended as a selection framework. Actual cost, performance and validation requirements must be calculated for the specific project.

How Should Pharmaceutical Teams Make the Final Packaging Decision?

The packaging decision should be made in two steps: first select the appropriate container or drug-delivery format, and then determine whether Bulk or RTU supply better matches the filling strategy.

RTU may be evaluated when filling-ready containers and reduced customer-side preparation are important. Bulk may remain suitable where validated washing, depyrogenation, sterilization and high-volume filling infrastructure already exist. PFS and cartridges become more relevant when the packaging must also support predetermined dosing or integration with a compatible drug-delivery device.

LINUO can support project discussions with product specifications, samples, applicable CoA and test data, packaging-format selection and relevant quality documentation. Customers can provide their formulation category, project stage, batch size, filling-line configuration, delivery method and target-market requirements for technical review.

Preguntas frecuentes

Is RTU packaging always better for clinical trials?

No. RTU packaging may reduce customer-side preparation and infrastructure requirements, making it worth evaluating for certain clinical projects. Final selection still depends on formulation, batch size, filling process, equipment and future scale-up plans.

Is Bulk packaging always less expensive than RTU?

Not necessarily. Bulk may have a lower container price in some projects, but the total comparison should include washing, WFI, depyrogenation, sterilization, cleanroom space, labour, maintenance, validation and handling.

Can RTU packaging be used for commercial production?

Yes, RTU formats can be evaluated for commercial production when capacity, filling-line compatibility, sterile barrier handling, documentation, supply continuity and total cost meet project requirements.

When should PFS packaging be considered?

PFS may be considered when the intended product requires a prefilled dose presentation or integration with an applicable injection device. Formulation, dose volume, components, filling process and administration method must be evaluated.

Why are cartridges used for GLP-1 and insulin projects?

LINUO identifies GLP-1 and insulin among the main glass-cartridge application areas. Cartridges can support compatible injection pens and pump systems where dimensional consistency, piston movement, siliconization and dosing performance are important.

Can a project switch from RTU to Bulk before commercialization?

A transition may be possible, but it requires review of the container, preparation process, filling line, stability programme, compatibility, documentation and validation requirements. It should not be treated as a simple packaging change.